BrainStorm posts $1.7M Q3 net loss as NurOwn Phase 3b ALS trial awaits start
The cell therapy developer reports minimal cash of about $0.35M while still preparing its ENDURANCE study in earlier-stage ALS under an FDA-agreed Special Protocol Assessment.
16 Nov 2026 · Brainstorm Cell Therapeutics Inc. BCLI · Company news
BrainStorm Cell Therapeutics reported results for the quarter ended 30 September 2026 on 16 November, disclosing a net loss of about $1.7M. Cash and restricted cash totalled roughly $0.35M at the end of the period.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Brainstorm Cell Therapeutics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Pipeline & R&DAll →
Pipeline & R&D
AEON Biopharma gets FDA Type 2b feedback on ABP-450 biosimilar route to BOTOX
16 Nov 2026 · AEON Biopharma, Inc. AEON · Company news
Pipeline & R&D
Connect Biopharma reports Q3 loss, plans FDA Phase 3 talks for rademikibart
16 Nov 2026 · Connect Biopharma Holdings Ltd CNTB · Company news
Pipeline & R&D
ORIC starts Phase 3 Himalayas-1 of rinzimetostat with Bayer's darolutamide in mCRPC
16 Nov 2026 · Oric Pharmaceuticals, Inc. ORIC · Company news
Pipeline & R&D
Enanta reports $68.2m annual loss as RSV drug zelicapavir moves through Phase 2b trials
16 Nov 2026 · Enanta Pharmaceuticals Inc ENTA · Company news
Pipeline & R&D
CervoMed presents interim 24-week NfL data for neflamapimod in nfvPPA at CTAD
16 Nov 2026 · CervoMed Inc. CRVO · Company news
Pipeline & R&D
Traws Pharma reports Phase 2a ratutrelvir data and plans Q4 resubmission for flu drug
16 Nov 2026 · Traws Pharma, Inc. TRAW · Company news